News >

Genomic Profiling Confirms MAPK/ERK Gene Alterations in Metastatic Prostate Cancer

Gina Columbus
Published: Thursday, Jun 27, 2019

Edwin Lin, MD/PhD Candidate

Edwin Lin, MD/PhD Candidate

MAPK/ERK gene alterations, primarily receptor tyrosine kinases (RTKs), BRAF, and CDK4/6 amplifications, were found to be present in more than half of patients with heavily pretreated metastatic prostate cancer, according to findings from a large cohort that were presented during the 2019 ASCO Annual Meeting.

“Future work to assess the biological and clinical significance of these recurrent patterns of alteration will pave the way for novel combinatorial treatments,” the authors concluded in the poster.
Lin E, Hahn AW, Sonpavde G, et al. Profiling of genomic alterations in MAPK/ERK signaling in a large cohort of metastatic prostate cancer (mPC) patients. J Clin Oncol. 2019;37(suppl; abstr 5032). doi: 10.1200/JCO.2019.37.15_suppl.5032.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication